Reference Interval:
By report
|
| Interpretive Data: |
Refer to report.
Refer to Statement A under Testing Information at http://www.aruplab.com.
|
| Note: |
Monoclonal antibody based therapies that target the CD20 antigen such as Rituximab® are being used to treat patients with a variety of B-cell lymphomas and leukemias. The effectiveness of these therapies requires that the B-cell leukemia or lymphoma cells express CD20. This test examines whether surface CD20 antigen expression can be identified on any B-cells present in the submitted specimen.
|
| CPT Code(s): |
88184 First marker and 88185 Each additional marker; AND 88187 interpretation for 2-8 markers
|
Cross References: |
CD20 on B Cells (B-Cell CD20 Expression), Rituximab Therapy CD20 (B-Cell CD20 Expression) |
![[ image for: Flow Cytometry Test Request Form Recommended]](icon_12.jpg){kind=icon}